Overview

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, prospective, non-randomized, feasibility study evaluating concurrent capecitabine-radiotherapy in participants with Resistant Breast Cancer.
Phase:
Phase 1
Details
Lead Sponsor:
A Bapsi Chakravarthy, MD
Treatments:
Capecitabine